Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 23, 2006, Pages 5968-5972

  Zhao, Zhijian ^a   O'Brien, Julie A ^a   Lemaire, Wei ^a   Williams Jr , David L ^a   Jacobson, Marlene A ^a   Sur, Cyrille ^a   Pettibone, Doug J ^a   Tiller, Philip R ^a   Smith, Sheri ^a   Hartman, George D ^a   Wolkenberg, Scott E ^a   Lindsley, Craig W ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

GlyT1; Inhibitor; Piperidine; Schizophrenia

Indexed keywords

BENZAMIDE DERIVATIVE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; NEUROLEPTIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

AMIDES; ANIMALS; BENZAMIDES; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; METHYLATION; MICE; MOLECULAR STRUCTURE; MORPHOLINES; PIPERIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33750499934     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.08.131     Document Type: Article

References (27)

1. Andreasen N.C. Brain Res. Rev. 31 (2000) 106
2. Karayiorgou M. Clin. Neurosci. Res. 1 (2001) 158
3. Meador-Woodruff J.H., and Healy D.J. Brain Res. Rev. 31 (2000) 288
4. Marino P.J., and Conn P.J. Curr. Drug Targets. CNS Neurol. Disord. 1 (2002) 1
5. Carlsson A., and Lindqvist M. Acta Pharmacol. Toxicol. 20 (1963) 140
6. Seeman P., Lee T., Chau-Wong M., and Wong K. Nature 261 (1976) 717
7. Seeman P., and Lee T. Science 188 (1975) 1217
8. Bertolino A., Breier A., Callicott J.H., Adler C., Mattay V.S., Shapiro M., Frank J.A., Pickar D., and Weinberger D.R. Neuropsychopharmacology 22 (1999) 125
9. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Proc. Natl. Acad. Sci. USA 93 (1996) 9235
10. Laruelle M., D'Souza C.D., Baldwin R.M., Abi-Dargham A., Kanes S.J., Fingado C.L., Seibyl J.P., Zoghbi S.S., Bowers M.B., Jatlow P., Charney D.S., and Innis R.B. Neuropsychopharmacology 17 (1997) 162
11. Angrist, B. M. In Amphetamine and its analogues, Cho; Segals, Eds.; Academic Press: San Diego, CA, 1994, pp 387-414.
12. Javitt D.C., and Zukin S.R. Am. J. Psychiatry 148 (1991) 1301
13. Olney J.W., and Farber N.B. Arch. Gen. Psychiatry 52 (1995) 998
14. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., and Lindenmayer J.P. Am. J. Psychiatry 151 (1994) 1234
15. Heresco-Levy U., Ermilov M., Lichtenberg P., Bar G., and Javitt D.C. Biol. Psychiatry 55 (2004) 165
16. Olney J.W., Newcomer J.W., and Farber N.B. J. Psychiatry Res. 33 (1999) 523
17. For a review. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams Jr. D.L., Sur C., and Kinney G.G. Curr. Topics Med. Chem. 8 (2006) 771
18. Danysz W., and Parsons A.C. Pharmacol. Rev. 50 (1998) 597
19. Smith K.E., Borden L.A., Hartig P.R., Branchek T., and Weinshank R.L. Neuron 8 (1992) 927
20. Borowsky B., Mezey E., and Hoffman B.J. Neuron 10 (1993) 851
21. Liu Q.R., Lopez-Corcuera B., Mandiyan S., Nelson H., and Nelson N. J. Biol. Chem. 268 (1993) 22802
22. Kim K.M., Kingsmore S.F., and Han H. Mol. Pharmacol. 45 (1994) 608
23. Morrow J.A., Collie I.T., Dunbar D.R., Walker G.B., Shahid M., and Hill D.R. FEBS Lett. 439 (1998) 334
24. Zarfa F., Gomeza J., Olivares L., Aragon C., and Gimenez C. Eur. J. Neurosci. 7 (1995) 1342
25. Lindsley C.W., Zhao Z., Leister W.H., O'Brien J.A., Lemiare W., Williams Jr. D.L., Chen T.-B., Chang R.S.L., Burno M., Jacobson M.A., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Tsou N.N., Duggan M.E., Conn P.J., and Hartman G.D. ChemMedChem 1 (2006) 807
26. Leister W.H., Strauss K.A., Wisnoski D.D., Zhao Z., and Lindsley C.W. J. Comb. Chem. 5 (2003) 322
27. Hochman J.H., Yamazaki M., Ohe T., and Lin J.H. Curr. Drug Methods 3 (2002) 257